Concepts (65)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pneumonia, Viral | 2 | 2020 | 318 | 0.390 |
Why?
|
| Fever | 1 | 2020 | 127 | 0.350 |
Why?
|
| C-Reactive Protein | 1 | 2020 | 194 | 0.350 |
Why?
|
| Lung Diseases, Interstitial | 2 | 2021 | 253 | 0.300 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2020 | 960 | 0.250 |
Why?
|
| Rheumatoid Factor | 1 | 2021 | 24 | 0.200 |
Why?
|
| Mediastinal Diseases | 1 | 2021 | 21 | 0.200 |
Why?
|
| Lymphadenopathy | 1 | 2021 | 18 | 0.200 |
Why?
|
| Inhalation Exposure | 1 | 2021 | 30 | 0.190 |
Why?
|
| Occupational Health | 1 | 2021 | 33 | 0.190 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2021 | 167 | 0.180 |
Why?
|
| Occupational Exposure | 1 | 2021 | 84 | 0.180 |
Why?
|
| Myeloblastin | 1 | 2019 | 5 | 0.170 |
Why?
|
| Deep Sedation | 1 | 2019 | 15 | 0.170 |
Why?
|
| Peroxidase | 1 | 2019 | 51 | 0.170 |
Why?
|
| Mortality | 1 | 2020 | 150 | 0.170 |
Why?
|
| Antibodies, Antineutrophil Cytoplasmic | 1 | 2019 | 21 | 0.170 |
Why?
|
| Idiopathic Interstitial Pneumonias | 1 | 2018 | 28 | 0.160 |
Why?
|
| Hypnotics and Sedatives | 1 | 2019 | 130 | 0.160 |
Why?
|
| Betacoronavirus | 1 | 2020 | 260 | 0.150 |
Why?
|
| Idiopathic Pulmonary Fibrosis | 1 | 2019 | 188 | 0.140 |
Why?
|
| Critical Illness | 1 | 2019 | 304 | 0.140 |
Why?
|
| Respiration, Artificial | 1 | 2019 | 350 | 0.140 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 303 | 0.130 |
Why?
|
| Sleep | 1 | 2019 | 447 | 0.130 |
Why?
|
| Carrier Proteins | 1 | 2018 | 679 | 0.130 |
Why?
|
| Hospitalization | 1 | 2020 | 869 | 0.120 |
Why?
|
| Pandemics | 1 | 2020 | 760 | 0.120 |
Why?
|
| Receptors, Interleukin-6 | 1 | 2020 | 17 | 0.100 |
Why?
|
| Aged | 6 | 2021 | 18904 | 0.090 |
Why?
|
| Drug Monitoring | 1 | 2020 | 119 | 0.090 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2020 | 342 | 0.080 |
Why?
|
| Time Factors | 2 | 2021 | 5309 | 0.080 |
Why?
|
| Male | 7 | 2021 | 41953 | 0.070 |
Why?
|
| Female | 7 | 2021 | 45687 | 0.070 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2020 | 1944 | 0.070 |
Why?
|
| Retrospective Studies | 4 | 2021 | 8869 | 0.070 |
Why?
|
| Prevalence | 2 | 2021 | 1248 | 0.070 |
Why?
|
| Severity of Illness Index | 1 | 2020 | 1842 | 0.060 |
Why?
|
| Middle Aged | 5 | 2021 | 25649 | 0.060 |
Why?
|
| Risk Assessment | 2 | 2021 | 2285 | 0.060 |
Why?
|
| United States | 3 | 2021 | 6877 | 0.060 |
Why?
|
| Prognosis | 2 | 2021 | 3749 | 0.060 |
Why?
|
| Prospective Studies | 2 | 2021 | 4268 | 0.050 |
Why?
|
| Humans | 7 | 2021 | 88482 | 0.050 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2020 | 76 | 0.050 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2021 | 2632 | 0.040 |
Why?
|
| Vasculitis | 1 | 2019 | 39 | 0.040 |
Why?
|
| Antibodies, Antinuclear | 1 | 2018 | 83 | 0.040 |
Why?
|
| Respiratory Function Tests | 1 | 2018 | 140 | 0.040 |
Why?
|
| Connective Tissue Diseases | 1 | 2018 | 69 | 0.040 |
Why?
|
| Treatment Outcome | 1 | 2020 | 8151 | 0.040 |
Why?
|
| Registries | 1 | 2021 | 754 | 0.040 |
Why?
|
| Autoimmunity | 1 | 2018 | 168 | 0.040 |
Why?
|
| Sex Factors | 1 | 2020 | 1063 | 0.040 |
Why?
|
| Disease Progression | 1 | 2021 | 1489 | 0.040 |
Why?
|
| Predictive Value of Tests | 1 | 2021 | 1704 | 0.040 |
Why?
|
| Radiography, Thoracic | 1 | 2018 | 319 | 0.040 |
Why?
|
| Age Factors | 1 | 2020 | 1860 | 0.030 |
Why?
|
| Biomarkers | 1 | 2021 | 1757 | 0.030 |
Why?
|
| Hypertension, Pulmonary | 1 | 2018 | 352 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2020 | 2833 | 0.030 |
Why?
|
| Lung | 1 | 2018 | 1243 | 0.030 |
Why?
|
| Risk Factors | 1 | 2021 | 5439 | 0.020 |
Why?
|
| Adult | 1 | 2021 | 26303 | 0.010 |
Why?
|